Vanguard Group Inc Vincerx Pharma, Inc. Transaction History

Vanguard Group Inc

$5.57 Trillion
Q4 2024

A detailed history of Vanguard Group Inc transactions in Vincerx Pharma, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 286,372 shares of VINC stock, worth $231,961. This represents 0.0% of its overall portfolio holdings.

Number of Shares

286,372

Previous 627,442 54.36%

Holding current value

$231,961

Previous $451,000 82.93%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	SELL	$0.19 - $0.73 $64,803 - $248,981	-341,070 Reduced 54.36%	286,372 $77,000
Q2 2024 Aug 13, 2024	SELL	$0.57 - $6.6 $22,545 - $261,049	-39,553 Reduced 5.93%	627,442 $508,000
Q1 2024 May 10, 2024	BUY	$1.07 - $8.06 $164,325 - $1.24 Million	153,575 Added 29.91%	666,995 $3.37 Million
Q3 2023 Nov 14, 2023	SELL	$0.66 - $1.38 $4,520 - $9,451	-6,849 Reduced 1.32%	513,420 $518,000
Q4 2022 Feb 10, 2023	SELL	$0.64 - $1.32 $1,207 - $2,490	-1,887 Reduced 0.36%	520,269 $530,000
Q3 2022 Nov 14, 2022	SELL	$0.0 - $1.72 $0 - $98,502	-57,269 Reduced 9.88%	522,156 $720,000
Q2 2022 Aug 12, 2022	SELL	$0.0 - $0.0 $0 - $0	-86,594 Reduced 13.0%	579,425 $765,000
Q1 2022 May 13, 2022	BUY	$0.0 - $0.0 $0 - $0	11,667 Added 1.78%	666,019 $2.66 Million
Q4 2021 Feb 14, 2022	BUY	$0.0 - $0.0 $0 - $0	119,317 Added 22.3%	654,352 $6.67 Million
Q3 2021 Nov 12, 2021	BUY	$0.0 - $0.0 $0 - $0	54,977 Added 11.45%	535,035 $8.65 Million
Q2 2021 Aug 13, 2021	BUY	$0.0 - $27.0 $0 - $13 Million	480,058 New	480,058 $6.24 Million

Others Institutions Holding VINC

# of Institutions

Shares Held

4.8M

Call Options Held

Put Options Held

View Full List

About Vincerx Pharma, Inc.

Ticker VINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,189,800
Market Cap $17.2M
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...

More about VINC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Vincerx Pharma, Inc. Transaction History